ANAnna O. Nyuganen

Anna O. Nyuganen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anna O. Nyuganen has a total of 49 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Comparative Analysis of Next-Generation Sequencing Data Processing Methods for Small RNA

    by L. M. Zabegina, M. S. Aleksandrova, A. Y. Garanin, A. V. Shalaev, P. A. Lokteva, A. O. Nyuganen, A. S. Artemyeva, S. V. Apalko, S. G. Sherbak, A. V. Malek

    Next-generation sequencing is the most accurate method for discovering new genetic biomarkers. While working with small RNAs, processing and interpreting sequencing data is challenging. Using follicular thyroid neoplasms as an example, four methods for analyzing sequencing results were compared for 24 samples: follicular adenoma (n = 12) and follicular carcinoma (n = 12). Sequencing was performed on the DNBSEQ platform. Obtained data were analyzed by four approaches (MirMaster 2.0, Salmon, Star, and Python3), results were compared using a number of criteria and validated with RT-PCR for several representative molecules. For the analysis of small RNA (microRNA) sequencing data, the advantage of algorithms that align reads to reference sequences of mature microRNAs without mismatches and insertions was demonstrated.

  • Open Access

    Comparison of outcomes of neoadjuvant chemotherapy in BRCA1- versus BRCA2-associated breast and ovarian cancers

    by Anna Sokolenko, Tatiana Gorodnova, Diana Enaldieva, Anna Shestakova, Alexandr Ivantsov, Anna Nyuganen, Igor Berlev, Petr Krivorotko, Alexey Belyaev, Evgeny Imyanitov

    Aim: BRCA1/2-associated breast and ovarian carcinomas are often regarded as a single entity, assuming that BRCA1 and BRCA2 genes are almost equivalent with regard to their clinical significance. However, BRCA1 and BRCA2 genes differ in their function; therefore, a comparison of treatment outcomes in BRCA1 vs. BRCA2 carriers is warranted. Methods: This study focused on consecutive patients treated with neoadjuvant chemotherapy (NACT), given that these subjects are treatment-naive and accessible for immediate assessment of pathological and clinical outcomes. Results: BRCA2-associated high-grade serous ovarian carcinomas (HGSOCs) demonstrated significantly higher rates of pathologic complete response (pCR) as compared to BRCA1-related cancers [8/15 (53%) vs. 7/48 (15%), P = 0.004]. In contrast, HER2-negative breast cancer (BC) patients showed a numerically higher rate of pCR in BRCA1 vs. BRCA2 mutation carriers [38/69 (55%) vs. 13/36 (36%), P = 0.1]. However, the comparison with BRCA-wild-type (WT) tumors revealed that this tendency was mainly attributed to the increased prevalence of hormone receptor (HR)-negative disease in the former group. When BC patients were stratified according to the tumor receptor status, the response rates in triple-negative patients were consistently higher than in HR+/HER2– patients across all analyzed subgroups [BRCA1: 35/59 (59%) vs. 3/10 (30%); BRCA2: 5/10 (50%) vs. 8/26 (31%); WT: 31/76 (41%) vs. 12/74 (16%); Mantel-Haenzsel P < 0.001]. Logistic regression analysis revealed that the odds ratio (OR) for achieving pCR was higher for receptor status (triple-negative vs. HR+: OR = 3.4, 95% CI 1.9–6.0, P < 0.001) than for BRCA status (any mutation vs. WT: OR = 2.1, 95% CI 1.2–3.6, P = 0.008). The addition of carboplatin did not improve pCR rates in BRCA1- or BRCA2-associated BCs, while there was a numerically higher efficacy of carboplatin-containing regimens in patients with WT triple-negative tumors [14/26 (54%) vs. 15/44 (34%), P = 0.13]. Conclusions: Hereditary ovarian carcinomas demonstrate better NACT outcomes in BRCA2 vs. BRCA1 mutation carriers. The opposite trend is observed in BC, which is likely to be attributed to a high frequency of triple-negative disease in BRCA1- but not BRCA2-associated BCs. Triple-negative receptor status rather than BRCA1/2 status is the strongest predictor of response to NACT in BC.


  • Assessment of Rat Spleen Structure under an Isolated and Combined Action of Selenium and Ethyl Carbamat

    by Ekaterina S. Samakina, Gleb Yu. Struchko, Larisa M. Merkulova, Olga Yu. Kostrova, Anna O. Nyuganen

    The immune system, having a complex structural organization, performs the main functions in providing an anti-inflammatory and antitumor immune response. The spleen, as a peripheral organ of the immune system, plays an important role in realization of these functions and contains a significant number of immune cells. Ethylcarbamate, being a group 2A carcinogen, can provoke the development of neoplastic processes through activation of Kras gene mutation and stimulation of oncogenic signals. Alongside with that, selenium affects the immune response, reducing the proliferation of tumor cells and producing an anti-inflammatory effect. Despite the existence of several studies on the effect of ethyl carbamate and selenium on the animal body, there is no data on the combined effect of these substances on the rat spleen under experimental conditions in the scientific literature. The aim of the study was to evaluate morphological and morphometric changes in the structure of the spleen in male rats with oral administration of selenium into their body and intraperitoneal injection of ethyl carbamate. Materials and methods of the study. The body mass of male rats and their spleen were studied, morphological and morphometric parameters of the spleen were evaluated, the lymphoid coefficient and the Kernoghan index were calculated. The animals were divided into four groups: N1 – control group; N2 – animals receiving selenium with drinking water; N3 – animals injected intraperitoneally with ethyl carbamate; N4 – animals receiving selenium with drinking water followed by injection of ethyl carbamate. Results. It was found that in the group 2, the area of lymphoid nodules was reduced, the Kernoghan index was reduced and the lymphoid coefficient was increased, while the body weight of rats and their spleen remained unchanged. In a month after an isolated intake of ethyl carbamate, both the body weight and the spleen weight in rats were significantly decreased. At this, in group 3, the area and the diameter of the germinal center, the thickness of the periarterial lymphoid sheath and the Kernoghan index were increased, and the lymphoid coefficient was reduced. At the ultramicroscopic level, an increase in the number of plasma cells was detected in group N3, as well as the number of swollen mitochondria in lymphocytes. In group 4, an increase in the area and the diameter of lymphoid nodules, the germinal center, as well as the lymphoid coefficient was determined, and the Kernoghan index was unchanged. When studying ultrathin sections in group 4 lymphocytes of various transitional forms were revealed. Conclusions. It was found that against the background of selenium intake into the body of male rats, a morphological rearrangement of the white pulp of the spleen occurred, probably associated with the reaction of T-lymphocytes. Ethyl carbamate injection resulted in a predominant effect on the B-cell link of the immune response of the spleen. In combined intake of selenium and ethyl carbamate, hyperplasia of the white pulp was revealed, consisting in an increase in its structures.


  • Open Access

    Endometrial expression of FOX proteins (FOXA1 and FOXA2) in women of reproductive age with different endometrial thickness: prospective cohort comparative study

    by Natalia V. Aganezova, Sergey S. Aganezov, Ksenia E. Gogichashvili, Anna S. Artemyeva, Anna O. Nyuganen

    Aim. To evaluate the expression of FOX proteins (FOXA1 and FOXA2) in the endometrium during the implantation window in women with a history of reproductive dysfunctions with different thickness of the endometrium. Materials and methods. The prospective cohort comparative study was conducted. The main group included patients with "thin" endometrium (7 mm according to ultrasound on preovulatory days; n=52), the comparison group consisted of women with normal endometrial thickness (7 mm according to ultrasound; n=62; women of both groups with reproductive dysfunctions of unknown reason), the control group included 16 healthy fertile women. Aspiration biopsy of the endometrium was performed on the 68 days after ovulation, as well as venipuncture to obtain a sample of peripheral blood to determine the levels of sex steroids (estradiol E2 and progesterone P). A combined histological and immunohistochemical study of endometrial biopsies was performed. Results. All women had ovulatory values of progesterone P16.1 nmol/l (68 days after ovulation) and normoestrogenemia (E2, pmol/l) in the blood. E2/P was similar in all groups (p0, 05). A pronounced expression of FOXA1 was noted in women with thin endometrium significantly more often (p0.05) with various hormone-receptor characteristics of the endometrium (42% n=22 out of 52) compared with healthy participants (0%; n=0). Reduced FOXA2 expression in the uterine mucosa was significantly more often detected on 68 days after ovulation in women with "thin" endometrium (56% n=29 of 52) than in women with normal endometrial thickness, both in women from the comparison group and in healthy women from the control group (p0.05). In a generalized analysis of the expression of FOX proteins in the endometrium on days 68 after ovulation, it was generally found that every second (50%; n=57 out of 114) women with a history of reproductive disorders (with a reduced and normal M-echo value) expression of proteomic markers differed from healthy women. In the case of "thin" endometrium, more than two thirds of patients (71%; n=37 out of 52) showed differences in endometrial expression of FOX proteins compared with women without a burdened reproductive history. Conclusion. In the majority of women (71%) with a thin endometrium and a history of reproductive dysfunctions, the expression of FOX proteins in the endometrium differed from the control group. Overall, endometrial expression of FOX proteins, which is likely to be different from healthy women, in patients with reproductive dysfunctions of unknown origin is a significant predictor of reproductive failure. At the same time, such an isolated indicator as M-echo value 7 mm according to ultrasound data is not an absolute prognostic marker of endometrial receptivity disorders.


  • Endometrial expression of leukemia-inhibiting factor in women of reproductive age with different endometrial thickness

    by N.V. Aganezova, S.S. Aganezov, K.E. Gogichashvili, A.S. Artemyeva, A.O. Niuganen

    ЦЕЛЬ ИССЛЕДОВАНИЯ Оценить экспрессию лейкемия-ингибирующего фактора (ЛИФ) в люминальном эпителии, железах и строме эндометрия в период «окна имплантации» у женщин с репродуктивной дисфункцией в анамнезе при различной толщине эндометрия. МАТЕРИАЛ И МЕТОДЫ Проведено проспективное когортное сравнительное исследование. В основную группу вошли пациентки с гипопластическим (n=52), в группу сравнения — женщины с нормальной толщиной эндометрия (n=62) (женщины обеих групп с репродуктивной дисфункцией неясного генеза), в группу контроля — здоровые фертильные женщины (n=16). Выполняли аспирационную биопсию эндометрия на 6—8-й день после овуляции с одномоментным получением образца периферической крови для определения уровней эстрадиола (E2) и прогестерона (P). Выполнено гистологическое и иммуногистохимическое исследование образцов эндометрия с определением экспрессии эстрогеновых (ER) и прогестероновых (PR) рецепторов и ЛИФ. РЕЗУЛЬТАТЫ Все участницы исследования имели овуляторные значения прогестерона (P≥16,1 нмоль/л, 6—8-й день после овуляции) и нормоэстрогенемию (Е2, пмоль/л). Е2/Р было сходным у женщин всех исследуемых групп (p>0,05). При сравнительном анализе с учетом толщины слизистой оболочки тела матки в соотношении с одновременными полноценными гормон-рецепторными характеристиками и достаточной выраженностью фазовой трансформации эндометрия выявлено, что у 20% женщин с репродуктивной дисфункцией и «тонким» эндометрием экспрессия ЛИФ в слизистой оболочке тела матки сходна с таковой у здоровых женщин. ЗАКЛЮЧЕНИЕ У 20% женщин с репродуктивной дисфункцией в анамнезе при «тонком» эндометрии выявлены показатели экспрессии рецепторов половых стероидов, протеомных маркеров (лейкемия-ингибирующего фактора) и фазовой трансформации эндометрия такие же, как у здоровых женщин. «Тонкий» эндометрий является предиктором бо́льшей частоты репродуктивных неудач, однако не представляется абсолютным прогностическим фактором таких нарушений. В ряде случаев женщины с синдромом гипопластического эндометрия способны забеременеть в естественном менструальном цикле с учетом адекватных характеристик рецептивности эндометрия.


  • Open Access

    Multiparametric Magnetic Resonance Imaging in Determining Prognostic Factors for Cervical Cancer IB2-IIB Stages after Neoadjuvant Chemotherapy

    by A. S. Mamontova, O. A. Smirnova, P. Yu. Grishko, A. O. Nyuganen, A. V. Kulish, S. A. Tyatkov, V. V. Gridasov, S. S. Bagnenko, I. V. Berlev, A. V. Mishchenko

    Мультипараметрическая магнитно-резонансная томография в определении прогностических факторов рака шейки матки IB2-IIB стадий после неоадъювантной химиотерапии


  • Open Access

    Results of dose-dense neoadjuvant chemotherapy in the treatment of stages IB2—IIB cervical cancer

    by A. S. Mamontova, O. A. Smirnova, A. O. Nyuganen, A. V. Abramova, S. S. Bagnenko, A. F. Urmancheeva, E. A. Ulrich, A. V. Mishchenko, I. V. Berlev

    Background. Applied standard methods of cervical cancer (CC) treatment have several disadvantages in terms of local and systemic toxicity and the risks of local recurrence. Our study proposed the use of neoadjuvant chemotherapy (NACT) in a dose-dense mode, followed by radical hysterectomy, in order to improve the results of treatment of locally advanced CC (IB2-IIB stages) (FIGO)/T1b2-2bN0M0 (TNM).Aim. Improvement of immediate and long-term results in treatment of locally advanced CC IB2-IIB stages (FIGO), determining the immediate effectiveness of dose-dense NACT, based on magnetic resonance imaging (MRI) data, and the identification of prognostic factors for tumor response to chemotherapy.Materials and methods. Between April 2016 to November 2019 120 women with IB2-IIB stages (FIGO) were included in this study. Of these, 58 patients underwent 3 cycles of intensified NACT according to the AP scheme (cisplatin 75 mg/m2, doxorubicin 35 mg/m2) and 62 patients underwent NACT according to the TR scheme (cisplatin 60 mg/m2, paclitaxel 60 mg/m2). The assessment of the effect of intensified NACT was performed according to the RECIST 1.1 criteria according to MRI data. Also 2 retrospective groups of patients were recruited: group I - surgical treatment without preoperative chemotherapy (25 patients with IB2-IB3 stages (FIGO) from November 2009 to August 2019), group II - concurrent chemoradiotherapy (44 patients with stage IIB cervical cancer (FIGO) from January 2013 to June 2018).Results. Complete clinical response was detected in 12 (10.0 %) patients, partial response - in 69 (57.5 %) patients, stable disease - in 35 (29.2 %) patients, progression was observed in 4 cases (3.3 %). After NACT in a dose dense mode, due to an objective clinical response (complete response, partial response and stable disease for stage IIA according to RECIST 1.1 criteria), 99 (82.5 %) patients underwent surgical treatment. For 21 (17.5 %) patients due to the absence achievement of objective clinical response (stable disease for stage IIB according to RECIST 1.1 criteria or progression), performed concurrent chemoradiotherapy. During the observation period, 113 (94.2 %) patients remained alive. Mortality for the first year was 1.7 % (2 cases). There was a coincidence of the results of a complete response according to MRI in 11 (91.7 %) cases out of 12 cases with the pathology data. According to multivariate analysis, it was revealed that parametrial invasion, according to the histological examination of the surgical material, is an independent prognostic factor for recurrence. According to comparative evaluation of disease-free survival curves between groups of IB2-IIB stages (FIGO) patients who received and did not receive dose-dense chemotherapy, it was found that disease- free survival in the group with NACT was higher compared to the group without NACT (p = 0.03, the log-rank criterion).Conclusions. The use of dose-dense NACT is an effective treatment mode for patients with IB2-IIB CC (FIGO), which in most cases allows achieving a tumor response with subsequent improvement in immediate and long-term results and can be considered as an alternative to standard treatment for locally advanced CC.


  • Open Access

    Evaluation of the antitumour activity of local intraperitoneal hyperthermia in a model of advanced high-grade ovarian carcinoma in rats

    by Ya. G. Murazov, A. L. Semenov, K. Yu. Senchik, A. O. Nyuganen, A. S. Artemyeva, A. M. Belyaev

    In our study we carried out an exploratory assessment of the antitumor activity of hyperthermic intraperitoneal perfusion (Hipep) with 0.9 % sodium chloride solution and compared it with the effect of a single normothermic intraperitoneal (i.p.) Administration of cisplatin in the maximum tolerated dose (mtd). Thirty-six mature female Wistar rats with transplanted i.p. Syngeneic ovarian carcinoma were randomized into three groups: control group (2 ml of 0.9 % sodium chloride i.p. At room temperature, n=12); cisplatin group (cisplatin 4 mg/kg i.p. At room temperature, n=12); Hipep group (open i.p. Perfusion with 0.9 % sodium chloride solution at a temperature of 40,5–41,5 °c for 45 minutes, n=12). The primary endpoint was the overall survival (os) of the animals in each of the three groups. The total peritoneal cancer index (pci), weight and degree of ascites haemorrhagia were assessed at autopsy. The median os in the control group, Hipep, and cisplatin was 19, 39, and 40 days, respectively (log-rank test р<0.0001). In comparison to the control group, the differences were statistically significant for both cisplatin (HR=0.22; 95 % ci: 0.08–0.62; log-rank test р<0.0001) and Hipep (HR=0.32; 95 % ci 0.13–0.82; log-rank test р=0.0013). There were no differences in os between the cisplatin and Hipep groups (log-rank test р=0.4853). The Hipep procedure was associated with a significant decrease in total pci, a tendency towards a decrease in the ascites weight and a higher severity of haemorrhagia. In terms of os, local hyperthermia, provided by Hipep without a cytostatic drug, was comparable with single normothermic i.p. Administration of cisplatin in mtd and exceeded the effects of the latter in relation to the development of peritoneal carcinomatosis.

  • Open Access

    Evaluation of the antitumor activity of 2-[3-(2-chloroethyl)-3-nitrosoureido]-1,3-propanediol (chlonisol) in C57BL/6 mice with intracranially transplanted B16 melanoma

    by I. G. Murazov, A. N. Stukov, Iu. G. Zmitrichenko, A. O. Niuganen, G. V. Tochilnikov, D. Ch. Latipova, L. V. Filatova, T. Yu. Semiglazova

    Background. The arsenal of antitumor drug therapy for melanoma brain metastases is limited. The search and study of new agents capable to penetrate the blood-brain barrier and provide a therapeutic effect against intracranial tumors remains an unmet clinical need. The aim is to evaluate the antitumor activity of the domestic derivative of nitrosoalkylureas, chlonisol, in mice with intracranially transplanted syngeneic B16 melanoma. Methods. The experiment was carried out in 18 female inbred C57BL/6 mice. After intracranial tumor transplantation, performed according to modified technique, the animals were randomized into two groups: I. Control (n = 10) – the animals were injected with normal saline 10 ml/kg intraperitoneally; II. Chlonisol (n = 8) – the animals were treated with the test compound at a dose of 15 mg/kg in normal saline intraperitoneally. The single administration of normal saline and chlonisol was performed 24 hours after tumor transplantation. The end point of the study was overall survival (OS) of the animals. Results. Compared with the control group, administration of chlonisol significantly increased the median OS of mice from 13 to 18 days (log rank test, p = 0.0005). Chlonisol significantly decreased the risk of death by 71 % compared with the control group (HR = 0.29; 95 %CI 0.10–0.82). By the 15th day after intracranial transplantation of B16 melanoma, all 10 mice in the control group died from intracerebral tumors (100 %), whereas in the chlonisol group only 2 out of 8 (25 %) mice died (Fisher's exact test, p = 0.0015). Conclusion. Despite the exploratory nature of the present study, it provides a good starting point for further research of chlonisol in brain tumors.


  • Evaluation of the chemopreventive potential of polyprenols from the needles of Picea abies L. and Pinus sylvestris L. using the model of prostate carcinogenesis in male Wistar rats

    by N.N. Petrov National Medical Research Center of Oncology of the Ministry of Healthcare of the Russian Federation, Ia.G. Murazov, A.O. Nyuganen, A.S. Artemyeva

    Оценка химиопрофилактического потенциала полипренолов из хвои Picea abies L. и Pinus sylvestris L. на модели канцерогенеза предстательной железы у